Dogwood Therapeutics, Inc. filed a Form 8-K on January 9, 2026, announcing the sale of 2,338,948 shares of common stock for approximately $12.5 million to an institutional investor as part of a registered direct offering along with private warrants; the offering closed on January 13, 2026. They also terminated a prior agreement for selling shares that had a potential offering price of $8.56 million, without incurring penalties.